As adenoma size correlates with the degree of hyperprolactinemia, optimal prolactin thresholds that account for the observed gender differences in both serum prolactin levels and adenoma size are warranted to robustly guide and triage these patients for optimal first-line therapy robustly. This evidence concerns the gene PRL and hyperprolactinemia.